A Phase 2 interventional study of BMS-986435 and Placebo in Heart Failure, sponsored by Bristol-Myers Squibb. Active, not recruiting at 86 sites in 11 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-30.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Heart Failure by Bristol-Myers Squibb — 1 open to participants now, 2 under way, none of them phase 3. Heart Failure · Bristol-Myers Squibb.
Among the 28 studies in Heart Failure by Bristol-Myers Squibb, this one is the 3rd largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2023, is one of 7 in phase 2, and was the 28th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
Browse Heart Failure studies →1 of the 28 studies in Heart Failure by Bristol-Myers Squibb is open now, in 9 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Austria, Czechia and 6 more countries
Ages 18+
By country, each count listing its studies:
Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 8 · Phase 3 1
First in 2002; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 227 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 54 across the 20 interventional studies, 1,425 across the 8 observational. Of the 24 that completed or were terminated, 6 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
1 of the studies in Heart Failure by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06122779Bristol-Myers SquibbStudy to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) | 2026-12-14 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies in Heart Failure by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability.
Exclusion Criteria
Drug: BMS-986435
Other: Placebo
Specified dose on specified days
Also known as: MYK-224
Specified dose on specified days
Incidence of treatment emergent adverse events (TEAEs)
Time frame: Up to approximately 24 weeks
Incidence of serious adverse events (SAEs)
Time frame: Up to approximately 24 weeks
Incidence of AEs leading to treatment discontinuation
Time frame: Up to approximately 20 weeks
Summary of plasma concentrations of MYK-224
Time frame: Up to approximately 20 weeks
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.
Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's planned 37 months is above that.
Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Delocamten